中文
| Catalogue |
|
|
| Recommend Products |
Company News
- Everest Medicines Enters into Exclusive Licensing Agreement with Dimerix 6/17/2026
- Everest Medicines Secures Exclusive License for Sumecigrel in Asia-Pacific, Expanding Its ... 6/11/2026
- Everest Medicines Enters Commercialization License Agreement with Mabworks for Bejescin(R)... 6/4/2026
- Everest Medicines Receives Shareholding Increase from Substantial Shareholder CBC Group, G... 5/25/2026
- Substantial Shareholder Wei Fu Increases Shareholding in Everest Medicines Again 5/15/2026
- Everest Medicines Announces Positive First-in-Human Data for Personalized mRNA Cancer Vacc... 4/23/2026
- Everest Medicines Enters into Asset Purchase Agreement for Etripamil Nasal Spray, Expandin... 3/25/2026
- Everest Medicines Announced the Commercial Launch of VELSIPITY(R) (Etrasimod Arginine Tabl... 3/15/2026
- Everest Medicines Shareholders Pass Resolutions Including Commercialization Service Agreem... 2/27/2026
- Everest Medicines Announces China NMPA Approval of VELSIPITY(R) for Adults with Moderately... 2/10/2026
- Everest Medicines Announces China NMPA Approval of VELSIPITY(R) for Adults with Moderately... 2/9/2026
- Everest Medicines Unveils 2030 Strategy as Directors and Substantial Shareholder Buy Over ... 12/16/2025
- Everest Medicines Announces Commercialization Service Agreement and License Agreement with... 12/13/2025
- Everest Medicines Acquires Exclusive Greater China and Other Asian Country Rights to VIS-1... 10/31/2025
- Everest Medicines Announces First Patient Enrolled in a Global Multi-Center Phase I Clinic... 10/20/2025
- 10/13/2025
- Everest Medicines Announces Publication of Etrasimod's Asian Multicenter Phase III ENLIGHT... 10/10/2025
- Everest Medicines' New Drug Application for Etrasimod Accepted in Taiwan 8/15/2025
- NEFECON(R) Receives NMPA Approval for Production Expansion in China 8/14/2025
- Everest Medicines Announces Full Approval of NEFECON(R) in Taiwan 8/12/2025